Phospholipase

Fuzapladib sodium (IS-741 sodium) is an effective orally active inhibitor of phospholipase A2 (phospholipase A2). Fuzapladib sodium can block the adhesion between inflammatory cells and microvascular endothelial cells, inhibit neutrophil infiltration into the pancreas or acute pancreatitis, and has anti-acute pancreatitis effects.

LFHP-1c is a PGAM5 inhibitor that exhibits neuroprotective activity in ischemic stroke. LFHP-1c protects the integrity of the blood-brain barrier from ischemic damage. LFHP-1c binds to endothelial cell PGAM5, inhibits PGAM5 phosphatase activity, and suppresses the interaction between PGAM5 and NRF2. LFHP-1c has protective effects both in vitro and in vivo.

SB-435495 is an effective, selective, reversible, non-covalent and orally active inhibitor of Lp-PLA2 with an IC50 of 0.06 nM.

ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM.

Giripladib (PLA-695) is a indole-based inhibitor of cytosolic phospholipase A2 (cPLA2).

A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15 μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis.

VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM.

VU533 (APE-PLD) activator is a potent NAPE-PLD activator with an EC50 value of 0.30 µM.

Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule.

VU0364739 is a selective PLD2 inhibitor (IC50: 22 nM).

Anti-CD3 Antibody (UCHT-1) is an antibody targeting CD3.

N-Palmitoyl-l-leucine (GK144) is a secreted phospholipases A 2 inhibitor.

BAPTA tetracesium is a selective and cell-impermeant chelator for calcium.

SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor.

A lipopeptide with enzyme inhibitory and immunosuppressant activities